Synonyms: compound 17 [Giannessi et al., 2003] | ST-1326 | ST1326
Compound class:
Synthetic organic
Comment: Teglicar (ST1326) is a reversible carnitine palmitoyltransferase inhibitor [2]. It is a substrate analogue that mimics palmitoylcarnitine. Teglicar has been investigated for anti-cancer effects in solid [1] and liquid tumours [3-5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Quantitative data were determined in mitochondial isolates from rat tissues [2]. Expression of CPT1A is assessed as being most significant in liver (where CPT1B is absent), and CPT1B in heart muscle. However CPT1A can also be detected in heart muscle. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Targets where the ligand is described in the comment field | |
Target | Comment |
carnitine palmitoyltransferase 2 | Loss of CPT2 function causes the rare lipid metabolism disorder carnitine palmitoyltransferase II deficiency, where long-chain fatty acids cannot be transported into mitochondria for processing and energy production via β-oxidation. The disorder can manifest as neonatal, infantile and adult forms which differ in their tissue-specific symptoms. The 3D stuctures of rat CPT2 in complex with teglicar (PDB ID 2FW3) [7] and a palmitoyl-carnitine substrate analogue (PDB ID 2RCU) [6] have been resolved. |